SECURE-C is intended for disc reconstruction and motion preservation at the disc under operation. The Investigational Device Exemption trial, inclusive of 380 patients, compared the SECURE-C to anterior cervical discectomy and fusion using a cervical plate and structural allograft. The patients suffered from intractable symptomatic cervical disc disease at a single level.
Here are seven-year, postsurgery data points:
1. Patients with the SECURE-C reported greater overall satisfaction compared to ACDF patients.
2. Of the SECURE-C group, 86.3 percent saw statistically superior composite overall success results compared to ACDF patients at 70 percent.
3. Eighty-six percent of the ACDF patients saw Neck Disability Index pain and function improvement compared to 90.4 percent of the SECURE-C group.
4. The SECURE-C patients experienced a lower rate of subsequent surgery at the operated level compared to ACDF patients.
5. ACDF patients had a higher rate of adjacent level surgery compared to SECURE-C patients.
More articles on devices:
SpineGuard receives 1st PediGuard order from Chinese medical group — 4 points
300th surgical spine case using K2M’s Rhine Cervical Disc System complete: 5 things to know
Stryker subsidiary settles trade secret case with Zimmer Biomet: 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
